308 related articles for article (PubMed ID: 31806595)
1. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
[TBL] [Abstract][Full Text] [Related]
3. Cluster Analysis of DSC MRI, Dynamic Contrast-Enhanced MRI, and DWI Parameters Associated with Prognosis in Patients with Glioblastoma after Removal of the Contrast-Enhancing Component: A Preliminary Study.
Chung H; Seo H; Choi SH; Park CK; Kim TM; Park SH; Won JK; Lee JH; Lee ST; Lee JY; Hwang I; Kang KM; Yun TJ
AJNR Am J Neuroradiol; 2022 Nov; 43(11):1559-1566. PubMed ID: 36175084
[TBL] [Abstract][Full Text] [Related]
4. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH
AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Predictions for Patients with Glioblastoma after Standard Treatment: Application of Contrast Leakage Information from DSC-MRI within Nonenhancing FLAIR High-Signal-Intensity Lesions.
Kim SH; Cho KH; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST
AJNR Am J Neuroradiol; 2019 Dec; 40(12):2052-2058. PubMed ID: 31727756
[TBL] [Abstract][Full Text] [Related]
6. The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival.
Choi YS; Kim DW; Lee SK; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Ahn SS
AJNR Am J Neuroradiol; 2015 Dec; 36(12):2235-41. PubMed ID: 26338911
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
[TBL] [Abstract][Full Text] [Related]
8. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.
Kim R; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
Eur Radiol; 2017 Mar; 27(3):1176-1185. PubMed ID: 27357131
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH
Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Progression-Free-Survival in Glioblastomas by Intratreatment Dynamic Contrast-Enhanced MRI.
Bisdas S; Smrdel U; Bajrovic FF; Surlan-Popovic K
Clin Neuroradiol; 2016 Mar; 26(1):39-45. PubMed ID: 25164691
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma.
Jo SW; Choi SH; Lee EJ; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
Korean J Radiol; 2021 Aug; 22(8):1369-1378. PubMed ID: 33987994
[TBL] [Abstract][Full Text] [Related]
12. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
[TBL] [Abstract][Full Text] [Related]
13. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
[TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST; Choi HJ; You SH; Kang KM; Yun TJ; Kim JH; Sohn CH
Eur Radiol; 2017 Aug; 27(8):3156-3166. PubMed ID: 27975145
[TBL] [Abstract][Full Text] [Related]
15. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
[TBL] [Abstract][Full Text] [Related]
16. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
17. Discrimination between Glioblastoma and Solitary Brain Metastasis: Comparison of Inflow-Based Vascular-Space-Occupancy and Dynamic Susceptibility Contrast MR Imaging.
Li X; Wang D; Liao S; Guo L; Xiao X; Liu X; Xu Y; Hua J; Pillai JJ; Wu Y
AJNR Am J Neuroradiol; 2020 Apr; 41(4):583-590. PubMed ID: 32139428
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral Heterogeneity of Glioblastoma Infiltration Revealed by Joint Histogram Analysis of Diffusion Tensor Imaging.
Li C; Wang S; Yan JL; Piper RJ; Liu H; Torheim T; Kim H; Zou J; Boonzaier NR; Sinha R; Matys T; Markowetz F; Price SJ
Neurosurgery; 2019 Oct; 85(4):524-534. PubMed ID: 30239840
[TBL] [Abstract][Full Text] [Related]
19. Mitotic Activity in Glioblastoma Correlates with Estimated Extravascular Extracellular Space Derived from Dynamic Contrast-Enhanced MR Imaging.
Mills SJ; du Plessis D; Pal P; Thompson G; Buonacorrsi G; Soh C; Parker GJ; Jackson A
AJNR Am J Neuroradiol; 2016 May; 37(5):811-7. PubMed ID: 26705318
[TBL] [Abstract][Full Text] [Related]
20. Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor.
Jain R; Poisson LM; Gutman D; Scarpace L; Hwang SN; Holder CA; Wintermark M; Rao A; Colen RR; Kirby J; Freymann J; Jaffe CC; Mikkelsen T; Flanders A
Radiology; 2014 Aug; 272(2):484-93. PubMed ID: 24646147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
